Metagenomi, Inc.MGXEarnings & Financial Report
Metagenomi, Inc. is a clinical-stage biotechnology company focused on developing metagenomics-powered gene editing therapeutics. It leverages massive microbial genome datasets to identify novel, precise CRISPR and alternative gene editing tools, advancing pipelines of in vivo and ex vivo therapies for both rare and common genetic diseases for global biopharma markets.
MGX Q4 FY2025 Key Financial Metrics
Revenue
$3.9M
Gross Profit
N/A
Operating Profit
$-24.4M
Net Profit
$-22.5M
Gross Margin
N/A
Operating Margin
-623.0%
Net Margin
-576.0%
YoY Growth
-59.3%
EPS
$-0.59
Metagenomi, Inc. Q4 FY2025 Financial Summary
Metagenomi, Inc. reported revenue of $3.9M (down 59.3% YoY) for Q4 FY2025, with a net profit of $-22.5M (up 3.7% YoY) (-576.0% margin).
Key Financial Metrics
| Total Revenue | $3.9M |
|---|---|
| Net Profit | $-22.5M |
| Gross Margin | N/A |
| Operating Margin | -623.0% |
| Report Period | Q4 FY2025 |
Metagenomi, Inc. Annual Revenue by Year
Metagenomi, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $25.2M).
Metagenomi, Inc. Quarterly Revenue & Net Profit History
Metagenomi, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.9M | -59.3% | $-22.5M | -576.0% |
| Q3 FY2025 | $8.7M | -24.8% | $-20.4M | -235.5% |
| Q2 FY2025 | $8.5M | -57.5% | $-19.9M | -233.9% |
| Q1 FY2025 | $4.1M | -63.0% | $-25.0M | -606.7% |
| Q4 FY2024 | $9.6M | — | $-23.4M | -243.4% |
| Q3 FY2024 | $11.5M | — | $-18.8M | -163.0% |
| Q2 FY2024 | $20.0M | — | $-10.7M | -53.7% |
| Q1 FY2024 | $11.2M | — | $-25.1M | -225.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.2M | $20.0M | $11.5M | $9.6M | $4.1M | $8.5M | $8.7M | $3.9M |
| YoY Growth | N/A | N/A | N/A | N/A | -63.0% | -57.5% | -24.8% | -59.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $415.4M | $385.9M | $358.3M | $324.6M | $297.9M | $272.3M | $247.9M | $221.1M |
| Liabilities | $139.8M | $116.5M | $102.6M | $89.7M | $85.2M | $76.5M | $69.5M | $62.5M |
| Equity | $275.6M | $269.4M | $255.8M | $234.9M | $212.7M | $195.8M | $178.4M | $158.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-29.9M | $-26.3M | $-26.6M | $-26.3M | $-22.8M | $-21.3M | $-21.3M | $-23.5M |